Our Bioplatform Approach: A Technical Advantage that Translates into a Business Advantage

By Jon Hu, CEO and Cofounder of Pepper Bio In the last decade, the tech industry has coined the phrase “software is eating the world.” In this decade, it’s going to be biotech that eats the world. Biotechnology, specifically, bioplatforms, are one of the main innovations changing our generation. Exhibit A: Moderna’s mRNA technology platform, which created the COVID-19 vaccine at an unprecedented rate, has changed how we perceive and interact…

Comments Off on Our Bioplatform Approach: A Technical Advantage that Translates into a Business Advantage

Move Over Multi-Omics – Meet Transomics, the Future of Drug Development

By Jon Hu, CEO and Cofounder of Pepper Bio  In the last century, we’ve seen incredible progress in the treatment and curing of human disease. Yet, scientists and drug developers still lack critical information about the variety of biological components that play a unique role in disease progression. For that reason, 3 out of 5 people worldwide still die of chronic inflammatory diseases, 1 of 6 die from cancer, and…

Comments Off on Move Over Multi-Omics – Meet Transomics, the Future of Drug Development

A Waze for Drug Discovery? Meet Pepper Bio.

By Jon Hu and Samantha Dale Strasser, PhD When we met over a decade ago as students at Northwestern University, we were struck by our similar experiences of watching our loved ones suffer from untreatable diseases and fighting our own.  Jon recounts, “when I was diagnosed with severe chronic migraines, doctors were able to find a prophylactic treatment regimen so that I could live a normal life. However, when my…

Comments Off on A Waze for Drug Discovery? Meet Pepper Bio.

NFX-backed Pepper Bio emerges from stealth with tools to hone in on complex diseases

There’s a clear pain point when it comes to drug discovery: Depending on which study you cite, creating an approved drug costs anywhere from $985 million to $2.6 billion. And R&D returns have rebounded to only about 2.5% in 2020, up from a low of 1.6% in 2019. Not to mention the fact that drugs that fail in clinical trials don’t actually help people who need new treatments. With a…

Comments Off on NFX-backed Pepper Bio emerges from stealth with tools to hone in on complex diseases
Read more about the article Pepper Bio Emerges from Stealth with ‘Waze for Drug Discovery’ Technology
Pepper Bio's partnership with Stanford's Dean Felsher will target Myc addicted cancers.

Pepper Bio Emerges from Stealth with ‘Waze for Drug Discovery’ Technology

Harvard, MIT, Cambridge, Brown & Northwestern Universities trained team leverages proprietary transomics translation technology to open a new era of drug discovery, rediscovery, and rescue. Pepper Bio, the world’s first transomics drug discovery company, emerges from stealth today to leverage its proprietary transomics -- including phosphoproteomics -- data translation technology to discover new drugs, rediscover new uses for existing therapeutics, and rescue drugs that may be on a course toward…

Comments Off on Pepper Bio Emerges from Stealth with ‘Waze for Drug Discovery’ Technology